Advanced Cancers Clinical Trial
Official title:
The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer
The goal of this research study is to learn if a type of light therapy can be used to help patients with advanced cancer who are having difficulty sleeping to sleep better.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned (as
in the flip of a coin) to one of two groups:
- Group 1 will receive one type of light therapy for 30 minutes every day for 14 days.
- Group 2 will receive a placebo light for 30 minutes every day for 14 days. The placebo
light is not designed to have any effect on your sleep.
You will not know which group you are in. After 14 days, both groups will begin receiving the
light therapy for another 14 days.
Litebook:
You will use a device called a Litebook to receive either the light therapy or the placebo
light for 30 minutes, within 2 hours of waking up every day. The Litebook is about the size
of a deck of cards. To use the Litebook, you will place it on a table within 2 feet of you
while you are sitting down. The Litebook will either deliver the light therapy or the placebo
light. You do not need to look directly into the Litebook and you can do usual activities
such as eating or reading while you are using it. The study staff will teach you how to use
the Litebook.
Study Diaries:
You will complete the following diaries at the end of each day of the 28-day study period:
- The light exposure diary about how much light you were exposed to.
- The sleep diary about your sleeping habits.
It should take about 5 minutes each day to make entries in the study diaries. You will return
the diaries to the study staff at 2 weeks and 4 weeks.
You will also wear a watch that will measure your activity level for 24 hours a day while you
are on study. You will return the watch to the study staff after you have completed the
study.
Questionnaires:
You will complete a questionnaire about any symptoms you are having from the light therapy at
the beginning of the study, at 1 week, at 2 weeks, and at 4 weeks. The questionnaire at 1
week can be done over the phone. It should take about 5 minutes to complete.
You will complete the following questionnaires at the beginning of the study, at 2 weeks, and
at 4 weeks:
- The Edmonton Symptom Assessment Scale. You will rate 10 symptoms such as tiredness,
shortness of breath, pain, and nausea.
- The FACIT-F questionnaire about how well you are able to perform the normal activities
of daily living, your quality of life, and how tired you are.
- The HADS questionnaire about your mood.
- The Pittsburgh Sleep Quality Index about your sleep quality, how long you sleep, and any
difficulties you are having when you are trying to sleep.
It should take about 25 minutes to complete all of the questionnaires.
Length of Study:
You will be on study for 28 days.
This is an investigational study. The use of light therapy in patients with difficulty
sleeping is investigational. It is currently being used for research purposes only.
Up to 152 patients will take part in this study. All will be enrolled at M. D. Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01213238 -
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
|
Phase 1 | |
Recruiting |
NCT02160366 -
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
|
||
Completed |
NCT00379353 -
The Effects of Thalidomide on Symptom Clusters
|
Phase 2 | |
Completed |
NCT00903708 -
LY2275796 in Advanced Cancer
|
Phase 1 | |
Terminated |
NCT00499382 -
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
|
N/A | |
Completed |
NCT02459964 -
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
|
Phase 4 | |
Completed |
NCT01430572 -
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
|
Phase 1 | |
Completed |
NCT02561234 -
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01375114 -
The Effects of Ginseng on Cancer-Related Fatigue
|
Phase 2 | |
Completed |
NCT01201694 -
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
|
Phase 1 | |
Completed |
NCT01454804 -
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT02801045 -
Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient
|
N/A | |
Completed |
NCT02873975 -
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
|
Phase 2 | |
Completed |
NCT01983969 -
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02272595 -
Rational Therapeutics Based on Matched Tumor and Normal Tissue
|
||
Active, not recruiting |
NCT01999491 -
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Recruiting |
NCT03375983 -
Plasmodium Immunotherapy for Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 | |
Withdrawn |
NCT01608139 -
Study of Curcumin, Vorinostat, and Sorafenib
|
Phase 1 | |
Completed |
NCT01024166 -
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
|
N/A |